<DOC>
	<DOCNO>NCT02926183</DOCNO>
	<brief_summary>Gemcitabine plus nub-paclitaxel ( GA ) regimen recently present international oncology meeting represent new standard regimen treatment metastatic pancreatic cancer . Therefore , decide consider balance safety efficacy survival time preoperative chemotherapy , investigator use NAC-GA regimen include two cycle ( three time weekly one week rest ) GA regimen .</brief_summary>
	<brief_title>Study NAC GA Therapy Patients With BRPC</brief_title>
	<detailed_description>Gemcitabine plus nub-paclitaxel ( GA ) regimen recently present international oncology meeting represent new standard regimen treatment metastatic pancreatic cancer . GA one high response rate treatment regimen , investigator consider promising treatment neoadjuvant chemotherapy . On hand , incidence grade 3 4 neutropenia , febrile neutropenia peripheral neuropathy significantly high g group compare gemcitabine group . Therefore , decide consider balance safety efficacy survival time preoperative chemotherapy , investigator use NAC-GA regimen include two cycle ( three time weekly one week rest ) GEMABR regimen . The investigator also evaluate Recurrence free survival first day protocol therapy , safety protocol therapy ( Adverse effect ) , morbidity base Clavien Dindo classification Grade 3 , response rate , preoperative/postoperative tumor marker ( CA19-9 , CEA ) , rate mornalization , reduction rate SUVmax value PET-CT ( limited PET-CT available institution ) , chemotherapeutic effect grade base Evans classification , resection rate , R0 resection rate , surgical data ( operative time , blood loss , transfusion , postoperative hospital day ) , overall morbidity rate ( Reoperation , rate re-admission , mortality ) , number patient rate postoperative adjuvant therapy ( entry rate , completion rate ) , dose intensity borderline resectable pancreatic cancer .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologically cytologically diagnose pancreatic adenocarcinoma , consistent NCCN guideline ( Version 2 . 2016 ) borderline resectablearterial , borderline resectablevenous 2 . Case measurable lesion 3 . First line treatment 4 . PS ( ECOG ) 01 5 . &gt; = 20 year old &lt; 80 year old 6 . The following criterion must satisfy laboratory test within 14 day registration WBC count &lt; =12,000/mm3 Neutrophil count &gt; =1,500/mm3 Hb &gt; = 9.0g/dl Plt &gt; = 100,000/mm3 T.Bil &lt; 2.0mg/dl ( &lt; 3=.0mg/dl biliary drainage case ) Serum Cr &lt; =upper limit normal ( ULN ) AST , ALT &lt; = 2.5xULN 7 . Written inform consent participate study 1 . Severe drug hypersensitivity 2 . Multiple primary cancer within 5 year 3 . Severe infection 4 . With grade2 severe peripheral neuropathy 5 . Interstitial pneumonia pulmonary fibrosis 6 . With uncontrollable pleural effusion ascites 7 . With uncontrollable diabetes mellitus 8 . With uncontrollable heart failure , angina , hypertension , arrhythmia 9 . With severe neurological/psychological symptom 10 . With watery diarrhea 11 . Pregnant lactate woman woman unknown suspect pregnancy 12 . Inappropriate patient entry study judgement investigator 13 . Diagnosed Resectable/Unresectable pancreatic carcinoma NCCN guideline ( Version 2.2016 )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>